Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CHina Adrenal Venous saMPling InvestigatiON (CHAMPION)

6. november 2026 opdateret af: Hui DONG, Chinese Academy of Medical Sciences, Fuwai Hospital

Kina Adrenal Venøs Prøvetagningsundersøgelse: En National Multicenter-undersøgelse

Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.

Studieoversigt

Detaljeret beskrivelse

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, yet its optimal diagnostic and therapeutic strategies remain challenging. Adrenal venous sampling (AVS) is regarded as the gold standard for subtype differentiation; however, important clinical, technical, and methodological issues have not been systematically addressed. This study is designed to comprehensively evaluate AVS and its clinical implications, aiming to elucidate the relationship between AVS-guided diagnosis and management of PA and long-term clinical and biochemical outcomes, while refining AVS protocols, standardizing clinical practice, optimizing therapeutic decision-making, and ultimately improving patient management and prognosis.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

5000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Anhui
      • Hefei, Anhui, Kina, 230036
        • Rekruttering
        • The first affiliated hospital of USTC
        • Kontakt:
        • Ledende efterforsker:
          • Xiangyong Kong, PhD
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100034
        • Rekruttering
        • Peking University First Hospital
        • Ledende efterforsker:
          • Wei Ma, MD
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 100044
        • Rekruttering
        • Peking University People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jing Liu, MD
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekruttering
        • China-Japan Friendship Hospital
        • Ledende efterforsker:
          • Wuqiang Che, MD
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 100022
        • Rekruttering
        • Chuiyangliu Hospital affiliated to Tsinghua University
        • Ledende efterforsker:
          • Lin Pi, MD
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 100037
        • Rekruttering
        • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
        • Ledende efterforsker:
          • Hui Dong, MD
        • Kontakt:
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 101100
        • Rekruttering
        • Beijing Luhe Hospital, Capital Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Dong Zhao, MD, PhD
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400000
        • Rekruttering
        • Chongqing University Central Hospital
        • Ledende efterforsker:
          • Dongying Zhang, MD
        • Kontakt:
      • Chongqing, Chongqing Municipality, Kina, 401147
        • Rekruttering
        • Chongqing General Hospital
        • Ledende efterforsker:
          • Rui He, MM
        • Kontakt:
      • Chongqing, Chongqing Municipality, Kina, 404100
        • Rekruttering
        • People's Hospital Affiliated to ChongqingThree Gorges Medical college
        • Ledende efterforsker:
          • Xianhu Luo, MD
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, Kina, 0591-87982222
        • Rekruttering
        • First Affiliated Hospital, Fujian Medical University, Fuzhou, China,
        • Kontakt:
        • Ledende efterforsker:
          • Feng Peng, MD
      • Xiamen, Fujian, Kina, 361016
        • Rekruttering
        • Cardiovascular Hospital Xiamen University
        • Ledende efterforsker:
          • Tao Ye, MD
        • Kontakt:
    • Gansu
      • Lanzhou, Gansu, Kina, 730000
        • Rekruttering
        • Lanzhou University Second Hospital
        • Ledende efterforsker:
          • Wei Liang, MD
        • Kontakt:
    • Guangdong
      • Foshan, Guangdong, Kina, 528211
        • Rekruttering
        • The Forth People's Hosptal of Nanhai District of Foshan City
        • Ledende efterforsker:
          • Yayan Han, MD
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 510080
        • Rekruttering
        • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
        • Ledende efterforsker:
          • Yingqing Feng, MD
        • Kontakt:
      • Shenzhen, Guangdong, Kina, 518000
        • Rekruttering
        • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
        • Kontakt:
        • Ledende efterforsker:
          • Jianqiong Kong, MD
      • Shenzhen, Guangdong, Kina, 518112
        • Rekruttering
        • Shenzhen Third People's Hospital,Shenzhen, Guangdong Province 518112, China
        • Kontakt:
        • Ledende efterforsker:
          • Zhenzhong Zheng, MD, PhD
      • Shenzhen, Guangdong, Kina, 518116
        • Rekruttering
        • Shenzhen Dapeng New District Kuiyong People's Hospital
        • Ledende efterforsker:
          • Tongqing Lu, MD
        • Kontakt:
    • Guangxi
      • Nanning, Guangxi, Kina, 530000
        • Rekruttering
        • The First Affiliated Hospital of Guangxi Medical University
        • Ledende efterforsker:
          • Jiangnan Huang, MD
        • Kontakt:
      • Nanning, Guangxi, Kina, 530007
        • Rekruttering
        • The Second Affliated Hospital Of GuangXi Medical Univesity
        • Kontakt:
        • Ledende efterforsker:
          • Houfa Ning, MM
      • Nanning, Guangxi, Kina, 547000
        • Rekruttering
        • Nanning Third People's Hospital
        • Kontakt:
          • Yongqi Xiao, MBBS
          • Telefonnummer: 07713394390
        • Ledende efterforsker:
          • Yongqi Xiao, MBBS
    • Guizhou
      • Guiyang, Guizhou, Kina, 550004
        • Rekruttering
        • The Affiliated Hospital of Guizhou Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Zhangrong Chen, MD
      • Guiyang, Guizhou, Kina, 550002
        • Rekruttering
        • Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China.
        • Kontakt:
        • Ledende efterforsker:
          • Fang Song, MD
      • Kaili, Guizhou, Kina, 556000
        • Rekruttering
        • The Second Affiliated Hospital Of Guizhou Medical University
        • Ledende efterforsker:
          • Yumei Xiang, MD
        • Kontakt:
    • Hainan
      • Haikou, Hainan, Kina, 570311
        • Rekruttering
        • Hainan General Hospital, Department of Endocrinology
        • Kontakt:
        • Ledende efterforsker:
          • Haiyu Zhang, MM
      • Hainan, Hainan, Kina, 570311
        • Rekruttering
        • Hainan General Hospital, Department of Cardiology
        • Kontakt:
        • Ledende efterforsker:
          • Wang Liao, MD
    • Hebei
      • Tangshan, Hebei, Kina, 063000
        • Rekruttering
        • Tangshan hongci Hospital
        • Ledende efterforsker:
          • Guijuan Zhang, MD
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • Rekruttering
        • The Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Shuo Zhang, MD
      • Harbin, Heilongjiang, Kina, 150001
        • Rekruttering
        • The First Affiliated Hospital of Harbin Medical University
        • Ledende efterforsker:
          • Dechao Zhao, MD
        • Kontakt:
    • Henan
      • Kaifeng, Henan, Kina, 475002
        • Rekruttering
        • Kai Feng the Peoples Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Qingli Pan, MD
      • Zhengzhou, Henan, Kina, 450052
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
        • Ledende efterforsker:
          • Youyou Du, MD
      • Zhengzhou, Henan, Kina, 450003
        • Rekruttering
        • Henan Provincial People's Hospital
        • Ledende efterforsker:
          • Min Liu, MD
        • Kontakt:
      • Zhengzhou, Henan, Kina, 450000
        • Rekruttering
        • Fuwai Central China Cardiovascular Hospital
        • Ledende efterforsker:
          • Qiuping Zhao, PhD
        • Kontakt:
      • Zhengzhou, Henan, Kina, 450018
        • Rekruttering
        • Zhengzhou Yihe Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Liang An, MD
      • Zhengzhou, Henan, Kina, 450007
        • Rekruttering
        • Zhengzhou Central Hospital Affiliated to Zhengzhou University
        • Ledende efterforsker:
          • Shuhua Yu, MM
        • Kontakt:
      • Zhoukou, Henan, Kina, 466000
        • Rekruttering
        • Zhoukou Central Hospital
        • Ledende efterforsker:
          • Baogong Wang, MD
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina, 430060
        • Rekruttering
        • Renmin Hospital of Wuhan University
        • Kontakt:
        • Ledende efterforsker:
          • Hongxin Xu, MD
      • Xiangyang, Hubei, Kina, 441021
        • Rekruttering
        • Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
        • Kontakt:
        • Ledende efterforsker:
          • Qingan Li, MD
      • Yichang, Hubei, Kina, 43000
        • Rekruttering
        • Yichang Central People's Hospital
        • Ledende efterforsker:
          • Yunbo Lv, MD
        • Kontakt:
    • Hunan
      • Zhuzhou, Hunan, Kina, 412000
        • Rekruttering
        • Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University
        • Kontakt:
          • Liang Tang, MBBS
          • Telefonnummer: 0733-28561703
        • Ledende efterforsker:
          • Liang Tang, MBBS
    • Jiangsu
      • Xuzhou, Jiangsu, Kina, 221009
        • Rekruttering
        • Xuzhou Central Hospital, Jiangsu
        • Kontakt:
        • Ledende efterforsker:
          • Hongyun Ruan, MD
    • Jiangxi
      • Ganzhou, Jiangxi, Kina, 341000
        • Rekruttering
        • The First Affiliated Hospital of Gannan Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Jiayuan Yuan, MD
      • Nanchang, Jiangxi, Kina, 330006
        • Rekruttering
        • Second Affiliated Hospital of Nanchang University
        • Kontakt:
        • Ledende efterforsker:
          • Yifei Dong, MD, PhD
      • Nanchang, Jiangxi, Kina, 330038
        • Rekruttering
        • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)
        • Ledende efterforsker:
          • Haohang Ruan, MBBS
        • Kontakt:
          • Haohang Ruan, MBBS
          • Telefonnummer: 0791-87721036
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Rekruttering
        • The First Hospital of Jilin University
        • Kontakt:
        • Ledende efterforsker:
          • Wei Zhao, MD
      • Changchun, Jilin, Kina, 130051
        • Rekruttering
        • Jilin Province FAW General Hospital
        • Ledende efterforsker:
          • Wenhai Wang, MM
        • Kontakt:
    • Liaoning
      • Dalian, Liaoning, Kina, 116001
        • Rekruttering
        • Affilated Zhongshan Hospital of Dalian University
        • Kontakt:
        • Ledende efterforsker:
          • Minglian Gong, MD
      • Dalian, Liaoning, Kina, 116011
        • Rekruttering
        • Frist Aiffiliated Hospital of Dalian Medical University
        • Ledende efterforsker:
          • Yinong Jiang, MD
        • Kontakt:
      • Dalian, Liaoning, Kina, 116027
        • Rekruttering
        • The second hospital of Dalian Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Nan Niu, MD
    • Neimenggu
      • Ulanhot, Neimenggu, Kina, 137400
        • Rekruttering
        • Inner Mongolia Xing'an League People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Tao Guo, MM
    • Ningxia
      • Yinchuan, Ningxia, Kina, 750000
        • Rekruttering
        • The First People's Hospital of Yinchuan
        • Kontakt:
        • Ledende efterforsker:
          • Fang Chen, PhD
    • Qinghai
      • Xining, Qinghai, Kina, 810001
        • Rekruttering
        • Qinghai University Affiliated Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Ming Ren, MM
      • Xining, Qinghai, Kina, 810000
        • Rekruttering
        • Qinghai Province Cardiovascular and Cerebrovascular Disease Specialist Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xiaozhou Wang, MD
    • Shandong
      • Jinan, Shandong, Kina, 250012
        • Rekruttering
        • Qilu Hospital of Shandong University
        • Ledende efterforsker:
          • Peili Bu, MD
        • Kontakt:
      • Jinan, Shandong, Kina, 250013
        • Rekruttering
        • Central Hospital Affiliated to Shandong First Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Rui Xu, MD, PhD
      • Jinan, Shandong, Kina, 250000
        • Rekruttering
        • the Second Hospital, Cheeloo College of Medicine, Shandong University
        • Kontakt:
        • Ledende efterforsker:
          • Qinghai Wang, MD
      • Liaocheng, Shandong, Kina, 252200
        • Rekruttering
        • People's Hospital of Donga County, Shandong Province
        • Ledende efterforsker:
          • Xiaoli Wang, MD
        • Kontakt:
      • Qingdao, Shandong, Kina, 266000
        • Rekruttering
        • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
        • Kontakt:
        • Ledende efterforsker:
          • Nan Jia, MD
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200025
        • Rekruttering
        • Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Jianzhong Xu, MD, PhD
      • Shanghai, Shanghai Municipality, Kina, 200062
        • Rekruttering
        • Shanghai Putuo District Central Hospital
        • Ledende efterforsker:
          • Zongjun Liu, MD
        • Kontakt:
      • Shanghai, Shanghai Municipality, Kina, 200080
        • Rekruttering
        • Shanghai General Hospital ( originally named Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Zhi Zhang, MD
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030001
        • Rekruttering
        • the second hospital of ShanXi medical unversity
        • Ledende efterforsker:
          • Bin Yang, MD
        • Kontakt:
      • Xi’an, Shanxi, Kina, 710018
        • Rekruttering
        • Xi'an People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kang Cheng, MD, PhD
    • Sichuan
      • Chengdu, Sichuan, Kina, 611130
        • Rekruttering
        • Chengdu Fifth People's Hospital
        • Ledende efterforsker:
          • Mingjian Lang, MD
        • Kontakt:
      • Chengdu, Sichuan, Kina, 610500
        • Rekruttering
        • The First Affiliated Hospital of Chengdu Medical College
        • Ledende efterforsker:
          • Peijian Wang, MD
        • Kontakt:
      • Chengdu, Sichuan, Kina, 610031
        • Rekruttering
        • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China
        • Ledende efterforsker:
          • Zhen Zhang, MD
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300052
        • Rekruttering
        • Tianjin Medical University General Hospital
        • Ledende efterforsker:
          • Dianxun Fu, MD
        • Kontakt:
      • Tianjin, Tianjin Municipality, Kina, 300211
        • Rekruttering
        • The Second Hospital of Tianjin Medical University
        • Ledende efterforsker:
          • Changle Liu, MD
        • Kontakt:
      • Tianjin, Tianjin Municipality, Kina, 300457
        • Rekruttering
        • TEDA International Cardiovascular Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Weiqiang Wang, MM
    • Tibet
      • Chamdo, Tibet, Kina, 854000
        • Rekruttering
        • Changdu People's Hospital of Tibet
        • Kontakt:
          • Rui Xiang, MD
          • Telefonnummer: 0895-4821745
        • Ledende efterforsker:
          • Rui Xiang, MD
    • Xinjiang
      • Yining, Xinjiang, Kina, 835000
        • Rekruttering
        • Yili Kazak Autonomous Prefecture Friendship Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Wei Li, MBBS
      • Ürümqi, Xinjiang, Kina, 830001
        • Rekruttering
        • Xinjiang Uygur Autonomous Region People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Guoliang Wang, PhD
    • Yunnan
      • Kunming, Yunnan, Kina, 650031
        • Rekruttering
        • The First Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Lihua Zhang, PhD
      • Kunming, Yunnan, Kina, 650102
        • Rekruttering
        • Fuwai Yunnan Cardiovascular Hospital
        • Ledende efterforsker:
          • Zihong Guo, MD
        • Kontakt:
      • Kunming, Yunnan, Kina, 650051
        • Rekruttering
        • Yan'an Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Yan He, MD
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310000
        • Rekruttering
        • Zhejiang Hospital
        • Ledende efterforsker:
          • Yimin Tang, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All patients with confirmed primary aldosteronism underwent adrenal venous sampling.

Beskrivelse

Inclusion Criteria:

  1. Patients with confirmed primary aldosteronism;
  2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.

Exclusion Criteria:

  1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months;
  2. An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L;
  3. Patients who refuse adrenalectomy;
  4. Suspected of having an adrenocortical carcinoma;
  5. Allergy to contrast agent;
  6. Pregnant, nursing, or planning to become pregnant

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Adrenal Venous Sampling

Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.

Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Major adverse cardiovascular events (MACE) at 1-year follow-up
Tidsramme: 1 year after AVS procedure

Incidence of major adverse cardiovascular events (MACE) at 1-year follow-up, including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.

1 year after AVS procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The success rate of left adrenal venous sampling
Tidsramme: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
The success rate of right adrenal venous sampling
Tidsramme: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
The success rate of bilateral adrenal venous sampling
Tidsramme: At AVS procedure

Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)

At AVS procedure
Selection of intraoperative catheter
Tidsramme: At AVS procedure

Types of catheter at the time of Adrenal Venous Sampling via antecubital approach or femoral approach

At AVS procedure
Time of the procedure
Tidsramme: At AVS procedure

Time of the procedure

At AVS procedure
Time of fluoroscopy
Tidsramme: At AVS procedure

Time of fluoroscopy

At AVS procedure
The contrast agent dosage
Tidsramme: At AVS procedure

The contrast agent dosage

At AVS procedure
the incidence of complications
Tidsramme: 1 week after AVS procedure

Complications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)

1 week after AVS procedure
the cost of the procedure
Tidsramme: At AVS procedure

the cost of the procedure

At AVS procedure
Change in 24-hour ambulatory systolic blood pressure
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in average systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) between baseline and each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in 24-hour ambulatory diastolic blood pressure
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in average diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) bewteen baseline and each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office systolic blood pressure
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in systolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office diastolic blood pressure
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in diastolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in antihypertensive medication burden
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in the number and/or dosage of antihypertensive medications taken by patients between baseline and each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in urinary albumin-to-creatinine ratio (UACR)
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The difference in urinary albumin-to-creatinine ratio measured at baseline and at each follow-up time point

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in left ventricular mass index (LVMI)
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in left ventricular mass index, as assessed by echocardiography, from baseline to each follow-up time point.

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in pulse wave velocity (PWV) from baseline
Tidsramme: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment

The change in pulse wave velocity measured between baseline and each follow-up time point。

At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Clinical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Tidsramme: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery

Clinical outcomes will be assessed at each follow-up visit afteradrenal surgery according to the PASO consensus criteria. Outcomes will be categorized as:

(1)Complete clinical success: normal blood pressure without the need for any antihypertensive medication. (2)Partial clinical success: improvement in blood pressure and/or a reduction in the number or dosage of antihypertensive medications. (3)Absent clinical success: no improvement in blood pressure or antihypertensive medication burden.

At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Biochemical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Tidsramme: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery

Biochemical outcomes will be assessed at each follow-up visit after adrenal surgery according to the PASO consensus classification. Outcomes will be categorized as:(1)Complete biochemical success: normal serum potassium levels and a normalized aldosterone-to-renin ratio (ARR) without the need for potassium supplementation.(2)Partial biochemical success: improvement in biochemical parameters without full normalization.(3)Absent biochemical success: no improvement in biochemical markers compared to baseline.

At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Major adverse cardiovascular events (MACE)
Tidsramme: At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure

Incidence of major adverse cardiovascular events (MACE), including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.

At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Hui Dong, MD, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. december 2025

Primær færdiggørelse (Anslået)

31. august 2029

Studieafslutning (Anslået)

31. august 2029

Datoer for studieregistrering

Først indsendt

19. november 2025

Først indsendt, der opfyldte QC-kriterier

19. november 2025

Først opslået (Faktiske)

26. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner